A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck
Start Date
April 24, 2018
End Date
March 14, 2025
Administered By
Duke Cancer Institute
Awarded By
Merck
Start Date
April 24, 2018
End Date
March 14, 2025